Loading clinical trials...
Loading clinical trials...
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-N...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT05636618 · Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, and more
NCT06790706 · Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, and more
NCT04609592 · Gastroenteropancreatic Neuroendocrine Tumor
NCT05262556 · Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, and more
NCT05987176 · Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, and more
Novartis Investigative Site
Alessandria
Novartis Investigative Site
Bologna
Novartis Investigative Site
Brescia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions